Sierra Oncology (Sierra Oncology) Net Cash per Share : $10.74 (As of Mar. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Sierra Oncology Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Sierra Oncology's Net Cash per Share for the quarter that ended in Mar. 2022 was $10.74.

The historical rank and industry rank for Sierra Oncology's Net Cash per Share or its related term are showing as below:

SRRA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.31 Med: 1.2 Max: 5.12
Current: 5.12

During the past 9 years, the highest Price-to-Net-Cash Ratio of Sierra Oncology was 5.12. The lowest was 0.31. And the median was 1.20.

SRRA's Price-to-Net-Cash is not ranked
in the Biotechnology industry.
Industry Median: 4.08 vs SRRA: 5.12

Sierra Oncology Net Cash per Share Historical Data

The historical data trend for Sierra Oncology's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sierra Oncology Net Cash per Share Chart

Sierra Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Cash per Share

Get a 7-Day Free Trial

70.90

48.98

44.21

8.49

5.87

Sierra Oncology Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Net Cash per Share	Get a 7-Day Free Trial															7.99	6.52	6.06	5.87	10.74

Competitive Comparison of Sierra Oncology's Net Cash per Share

For the Biotechnology subindustry, Sierra Oncology's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sierra Oncology's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sierra Oncology's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Sierra Oncology's Price-to-Net-Cash falls into.

Sierra Oncology Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Sierra Oncology's Net Cash per Share for the fiscal year that ended in Dec. 2021 is calculated as

	Net Cash per Share (A: Dec. 2021 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(104.749	-	13.369	-	0)	/	15.5717
=	5.87

Sierra Oncology's Net Cash per Share for the quarter that ended in Mar. 2022 is calculated as

	Net Cash per Share (Q: Mar. 2022 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(274.015	-	18.378	-	0)	/	23.8004
=	10.74

Sierra Oncology (NAS:SRRA) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Sierra Oncology Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Sierra Oncology's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sierra Oncology (Sierra Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sierra Oncology Inc (NAS:SRRA) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1820 Gateway Drive, Suite 110, San Mateo, USA, 94404

Website

https://www.sierraoncology.com

Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.

Executives

Vivo Opportunity Fund Holdings, L.p.	director, 10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
William D. Turner	officer: Chief Reg & Tech Ops Officer	C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Mary Christina Thomson	officer: General Counsel	C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Joshua Richardson	director, 10 percent owner	C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Longitude Prime Fund, L.p.	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Gaurav Aggarwal	director, 10 percent owner	C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Vivo Opportunity Fund, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Andrew Sinclair	director	C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Georgia Erbez	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459